Know Cancer

forgot password

A Study of the Safety, Tolerability, and Pharamcokinetics of MORAb-003, a Humanized Monoclonal Antibody, in Subjects With Advanced Ovarian Cancer

Phase 1
18 Years
Not Enrolling
Epithelial Ovarian Cancer

Thank you

Trial Information

A Study of the Safety, Tolerability, and Pharamcokinetics of MORAb-003, a Humanized Monoclonal Antibody, in Subjects With Advanced Ovarian Cancer

Inclusion Criteria:

1. Female subjects, ≥18 years of age, with a histologically confirmed epithelial
ovarian, fallopian tube, or primary peritoneal adenocarcinoma, with or without
elevation of CA 125, confirmed at the Department of Pathology, Memorial
Sloan-Kettering Cancer Center.

2. Subject must have disease, as defined by Response Evaluation Criteria in Solid Tumors
(RECIST) or evaluable by clinical signs/symptoms (e.g., ascites, pleural effusion, or
lesions of less than 2 cm) supported by CA-125, radiologic, or pathologic studies
conducted within 4 weeks prior to study entry.

3. Subject must have failed at least a standard (platinum-containing) chemotherapy
regimen and be considered platinum refractory or resistant.

4. Life expectancy ≥3 months, as estimated by the investigator.

5. Karnofsky performance status ≥70%.

6. Subjects must be surgically sterile, postmenopausal, or using an effective form of

7. Subjects undergoing treatment with other medications must have been on a stable
medication regimen for at least 30 days prior to Study Day 1.

8. Laboratory and clinical results within the 2 weeks prior to Study Day 1 as follows:

Absolute neutrophil count (ANC) ≥1.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin
≥10 g/dL Serum bilirubin ≤2.0 mg/dL Aspartate transaminase (AST) ≤2.5 x upper limit
of normal (ULN) Alanine transaminase (ALT) ≤2.5 x ULN Serum creatinine ≤2.0 mg/dL
Amylase ≤1.5 x ULN Lipase ≤1.5 x ULN

9. Spirometry indicating a FEV1 of >79% of predicted.

10. Subject must be willing and able to provide written informed consent.

Exclusion Criteria:

1. Known central nervous system (CNS) tumor involvement.

2. Evidence of other active malignancy.

3. Active asthma or other chronic lung disease.

4. Clinically significant heart disease (e.g., congestive heart failure of New York
Heart Association Class III or IV, angina not well controlled by medication, or
myocardial infarction within 6 months).

5. ECG demonstrating clinically significant arrhythmias (Note: Subjects with chronic
atrial arrhythmia, i.e., atrial fibrillation or paroxysmal SVT, are eligible).

6. Active serious systemic disease, including active bacterial or fungal infection.

7. Chronic inflammatory bowel disease.

8. Chemotherapy, biologic therapy, or immunotherapy within 3 weeks prior to enrollment.

9. Breast-feeding, pregnant, or likely to become pregnant during the study.

10. Active hepatitis or HIV infection.

11. Subjects who have received a previous monoclonal antibody therapy and have evidence
of an immune or allergic reaction, or documented HAHA.

12. Subjects with large ascites (≥500 cc based on results of most recent CT scan).

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Jason Konner, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

June 2005

Completion Date:

December 2007

Related Keywords:

  • Epithelial Ovarian Cancer
  • Ovarian Neoplasms
  • Neoplasms, Glandular and Epithelial



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021